Loading
A phase 2/3 trial of AMT-116 and ramucirumab in lung cancer, run by Multitude Therapeutics Inc., not yet recruiting.
Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy is a phase 2/3, randomised interventional study registered as NCT07718737 by Multitude Therapeutics Inc., with a registry enrolment figure of 512 participants, started 2026-08-28 and due to reach its primary completion in 2028-03-30. Interventions recorded: AMT-116; Investigator's choice regimens (docetaxel or docetaxel plus ramucirumab). Conditions listed: NSCLC (Advanced Non-small Cell Lung Cancer). Primary outcome: Number of Participants with Adverse Events as Assessed by CTCAE v6.0. Lung eligibility wording from the registry: "Diagnosed with non-squamous non-small cell lung cancer (NSCLC) confirmed by pathological or cytological tests". Sites: Australia, United States. No results are recorded here; the registry entry is the source.
Shares Ramucirumab, EGFR-mutated non-small-cell lung cancer, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Monoclonal antibodies and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Monoclonal antibodies and the tag lung-deep-dive.
Shares Ramucirumab, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Monoclonal antibodies and the tag lung-deep-dive.
Shares Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Monoclonal antibodies and the tag lung-deep-dive.
Shares Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Monoclonal antibodies and the tag lung-deep-dive.
Shares Ramucirumab, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Monoclonal antibodies and the tag lung-deep-dive.
Shares Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Monoclonal antibodies and the tag lung-deep-dive.